Literature DB >> 16796527

Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques.

Agneta S von Gegerfelt1, Candido Alicea, Antonio Valentin, Matthew Morrow, Koen K A van Rompay, Mila Ayash-Rashkovsky, Phillip Markham, James G Else, Marta L Marthas, George N Pavlakis, Ruth M Ruprecht, Barbara K Felber.   

Abstract

A cohort of 22 rhesus macaques of Indian origin infected as neonates, juveniles, or adults by Rev-independent strains of SIV was monitored over several years. After the initial acute phase, virus replication was controlled and plasma virus loads were persistently below the threshold of the assay. The animals were monitored for up to 7.6 years after infection for viral loads, cellular and humoral immune responses, hematological changes, and overall health and no signs of immune dysfunction or AIDS were observed. This study represents several years of additional observation compared to the previously published results, and indicates that the Rev-independent SIV clones tested do not cause AIDS-like progressive disease within 7.6 years from infection. All the animals showed persistent humoral and cellular SIV-specific immune responses, consistent with chronic infection. Different Rev-independent SIV strains showed similar properties and lack of pathogenicity. Multicolor flow cytometric analysis demonstrated preservation of the Central Memory subset of T cells in the attenuated SIV-infected animals. This study demonstrates a potent, long-lasting control of the Rev-independent attenuated SIV in macaques independent of the age at virus exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796527     DOI: 10.1089/aid.2006.22.516

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

Authors:  Agneta von Gegerfelt; Antonio Valentin; Candido Alicea; Koen K A Van Rompay; Marta L Marthas; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2010-08-11       Impact factor: 5.422

2.  RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs.

Authors:  Sergey Smulevitch; Jenifer Bear; Candido Alicea; Margherita Rosati; Rashmi Jalah; Andrei S Zolotukhin; Agneta von Gegerfelt; Daniel Michalowski; Christoph Moroni; George N Pavlakis; Barbara K Felber
Journal:  Retrovirology       Date:  2006-01-13       Impact factor: 4.602

3.  Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.

Authors:  Konstantin Virnik; Max Hockenbury; Yisheng Ni; Joel Beren; George N Pavlakis; Barbara K Felber; Ira Berkower
Journal:  Retrovirology       Date:  2013-09-16       Impact factor: 4.602

Review 4.  HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Authors:  Barbara K Felber; Antonio Valentin; Margherita Rosati; Cristina Bergamaschi; George N Pavlakis
Journal:  Vaccines (Basel)       Date:  2014-05-14

5.  Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques.

Authors:  Siddappa N Byrareddy; Mila Ayash-Rashkovsky; Victor G Kramer; Sandra J Lee; Mick Correll; Francis J Novembre; Francois Villinger; Welkin E Johnson; Agneta von Gegerfelt; Barbara K Felber; Ruth M Ruprecht
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

6.  The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.

Authors:  Eric Fleta-Soriano; Javier P Martinez; Bettina Hinkelmann; Klaus Gerth; Peter Washausen; Juana Diez; Ronald Frank; Florenz Sasse; Andreas Meyerhans
Journal:  Microb Cell Fact       Date:  2014-01-29       Impact factor: 5.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.